Epitech Group and Horus Pharma join forces to advance research in eye health
Epitech Group S.p.A. and Horus Pharma, a French pharmaceutical company specialized in ophthalmology, have signed a worldwide licensing agreement for the development of Adelmidrol in human ophthalmology and periocular dermatology applications.
The agreement marks an important milestone in Epitech Group’s research and development journey, marking its entry into the ophthalmological sector through the valorization of a proprietary molecule belonging to the ALIAmides family.
From ALIAmides research to new perspectives on eye health
Adelmidrol is the result of Epitech Group’s multi-decade research into ALIAmides, a family of molecules studied for their role in the physiological mechanisms regulating neuro-immune responses.
This scientific pathway stems from Rita Levi-Montalcini’s studies on the ALIA (Autacoid Local Injury Antagonism) mechanism, which guided Epitech Group in developing an approach focused on biomodulation and supporting the body’s natural self-regulatory systems.
Adelmidrol represents one of the tangible expressions of this scientific heritage. The partnership with Horus Pharma stems from a shared commitment to further explore its potential in ophthalmology, building on scientific knowledge of physiological mechanisms alongside the specialized expertise of both companies.
An international partnership built on complementary expertise
Horus Pharma brings over twenty years of experience in ophthalmology and a well-established commitment to innovation in eye health and dermo-ophthalmology.
The collaboration brings together Epitech Group’s scientific and technological know-how with Horus Pharma’s sector expertise, development capabilities, and international footprint.
The agreement confirms Epitech Group’s commitment to advancing its scientific heritage through new applications, strategic partnerships and international development pathways, broadening the horizons of ALIAmides research.

